在心脏手术中levosimendan治疗的影响:随机对照试验的网络元分析
Binlu Zhu1, Wanling Zhao1, Yifei Li1
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Frontiers in cardiovascular medicine
|February 27, 2026
概括
莱沃西门丹改善了心脏指数,并减少了心脏手术患者的重症监护室 (ICU) 停留时间. 然而,它没有提供显著的脏保护,表明需要对其整体安全性和有效性的进一步研究.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于对其有效性和安全性的证据不一致,为心脏手术患者使用levosimendan存在争议.
- 以前的研究在设计上有所不同,元分析经常使用有限的比较,使levosimendan的相对益处不清楚.
研究的目的:
- 进行一个系统的网络元分析,比较外科手术期间的Levosimendan与安慰剂和其他异型药物.
- 评估levosimendan在心脏手术中的益处和风险,重点关注血液动力学功能,脏保护和ICU住院.
主要方法:
- 一项系统的文献搜索确定了截至2024年12月的随机对照试验 (RCT).
- 主要结局包括心脏指数,中央静脉压,平均动脉压,ICU停留时间和肌水平.
- 网络元分析和累积排名曲线下的面积 (SUCRA) 用于比较和排名.
主要成果:
- 与安慰剂相比,Levosimendan增加了术后心脏指数 (SMD 1.16) 和降低了与多布他胺相比的平均动脉压 (SMD -0.93).
- 米利诺尼降低了CVP与多布他明和安慰剂相比. 与milrinone相比,levosimendan增加了心肺动脉压力.
- 与多布他胺相比,levosimendan和milrinone都缩短了ICU停留时间;在肌素水平上没有发现显著差异.
结论:
- 莱沃西门丹增强了手术后的血液动力学参数,包括心脏指数,并减少了ICU停留时间,与多布胺相比.
- 莱沃西门丹没有通过肌氨酸水平测量显著的脏保护作用.
- 这些发现突出了levosimendan的血液动力学益处,但强调了缺乏证据的脏保护在这种情况下.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
400
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
400
01:26Mitral Stenosis III: Medical Management
365
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
365
01:30Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.0K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.0K